tradingkey.logo

Evotec SE

EVO
3.130USD
-0.010-0.32%
Cierre 12/24, 13:00ETCotizaciones retrasadas 15 min
1.11BCap. mercado
PérdidaP/E TTM

Más Datos de Evotec SE Compañía

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Información de Evotec SE

Símbolo de cotizaciónEVO
Nombre de la empresaEvotec SE
Fecha de salida a bolsaOct 11, 1999
Director ejecutivoWojczewski (Christian)
Número de empleados4827
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 11
DirecciónEssener Bogen 7
CiudadHAMBURG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal22419
Teléfono4940560810
Sitio Webhttps://www.evotec.com/
Símbolo de cotizaciónEVO
Fecha de salida a bolsaOct 11, 1999
Director ejecutivoWojczewski (Christian)

Ejecutivos de Evotec SE

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Mr. Wesley Wheeler
Mr. Wesley Wheeler
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Constanze Ulmer-Eilfort
Dr. Constanze Ulmer-Eilfort
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mrs. Aurelie Dalbiez
Mrs. Aurelie Dalbiez
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Cord Dohrmann, Ph.D.
Dr. Cord Dohrmann, Ph.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Ms. Laetitia Rouxel
Ms. Laetitia Rouxel
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Mr. Wesley Wheeler
Mr. Wesley Wheeler
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2024
FY2023
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
482.23M
55.94%
Switzerland
117.94M
13.68%
United Kingdom
100.06M
11.61%
Rest of the world
89.00M
10.32%
Germany
35.59M
4.13%
Otro
37.16M
4.31%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Mubadala Investment Company PJSC
1.29%
Wellington Management Company, LLP
0.40%
BlackRock Institutional Trust Company, N.A.
0.36%
DCF Advisers, LLC
0.34%
WCM Investment Management
0.08%
Otro
97.52%
Accionistas
Accionistas
Proporción
Mubadala Investment Company PJSC
1.29%
Wellington Management Company, LLP
0.40%
BlackRock Institutional Trust Company, N.A.
0.36%
DCF Advisers, LLC
0.34%
WCM Investment Management
0.08%
Otro
97.52%
Tipos de accionistas
Accionistas
Proporción
Sovereign Wealth Fund
1.29%
Investment Advisor
0.94%
Investment Advisor/Hedge Fund
0.42%
Family Office
0.05%
Hedge Fund
0.04%
Research Firm
0.01%
Otro
97.24%

Participación institucional

Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
76
9.39M
2.97%
--
2025Q3
77
9.39M
2.97%
-16.64K
2025Q2
74
9.40M
2.85%
+334.04K
2025Q1
60
9.08M
2.82%
-923.30K
2024Q4
59
8.93M
2.90%
+634.42K
2024Q3
56
8.37M
3.36%
+770.57K
2024Q2
55
7.62M
2.73%
+2.19M
2024Q1
54
5.00M
2.98%
-5.56M
2023Q4
57
5.71M
1.76%
+4.47M
2023Q3
51
1.23M
1.80%
-162.10K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Mubadala Investment Company PJSC
4.60M
1.29%
--
--
Jun 30, 2025
Wellington Management Company, LLP
1.21M
0.34%
-697.85K
-36.66%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
0.37%
-184.93K
-12.32%
Jun 30, 2025
DCF Advisers, LLC
1.11M
0.31%
+362.91K
+48.29%
Jun 30, 2025
WCM Investment Management
297.91K
0.08%
+297.91K
--
Jun 30, 2025
Parametric Portfolio Associates LLC
303.50K
0.09%
+303.50K
--
Jun 30, 2025
Pitcairn
261.18K
0.07%
+261.18K
--
Jun 30, 2025
Citadel Advisors LLC
33.57K
0.01%
+33.57K
--
Jun 30, 2025
LPL Financial LLC
37.84K
0.01%
+37.84K
--
Jun 30, 2025
Envestnet Asset Management, Inc.
91.66K
0.03%
+91.66K
--
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Biotechnology ETF
0.08%
ActivePassive International Equity ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
Proporción0.08%
ActivePassive International Equity ETF
Proporción0%
DFA Dimensional Intl Sustainability Core 1 ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Evotec SE?

Los cinco principales accionistas de Evotec SE son:
Mubadala Investment Company PJSC posee 4.60M acciones, lo que representa el 1.29% del total de acciones.
Wellington Management Company, LLP posee 1.21M acciones, lo que representa el 0.34% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 1.32M acciones, lo que representa el 0.37% del total de acciones.
DCF Advisers, LLC posee 1.11M acciones, lo que representa el 0.31% del total de acciones.
WCM Investment Management posee 297.91K acciones, lo que representa el 0.08% del total de acciones.

¿Cuáles son los tres principales tipos de accionista de Evotec SE?

Los tres principales tipos de accionista de Evotec SE son:
Mubadala Investment Company PJSC
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.

¿Cuántas instituciones poseen acciones de Evotec SE (EVO)?

A fecha de 2025Q4, 76 instituciones poseen acciones de Evotec SE, con un valor de mercado combinado de aproximadamente 9.39M, lo que representa el 2.97% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.00%.

¿Cuál es la mayor fuente de ganancias de Evotec SE?

El FY2024, el segmento empresarial -- generó la ganancia más alta para Evotec SE, ascendiendo a -- y representando el --% de la ganancia total.
KeyAI